| 摘要: |
| 目的：探讨重组人生长激素联合亮丙瑞林对特发性中枢性性早熟女童的治疗效果及对雌二醇（E2）、促卵泡成熟激素（FSH）及黄体生成激素（LH）水平的影响。方法：选取2016-2018我院收治的56例特发性中枢性性早熟女童，按随机数表法分为治疗组和对照组各28例，对照组单用亮丙瑞林治疗，治疗组在对照组治疗基础上加用重组人生长激素，观察两组治疗后的骨龄（BA）、体质量指数（BMI）、预测成年身高（PAH-BA）、骨龄别身高标准差分值（HtSDS-BA）和年化平均生长速度（△GV）。结果：两组患儿乳房发育年龄、治疗时年龄、身高、BA、PAH-BA、HtSDS-BA、遗传靶身高、BMI、左卵巢容积、右卵巢容积、子宫容积和△G比较差异均无统计学意义（P>0.05）。治疗后两组患儿性激素水平（E2、LH、FSH）均显著下降，且治疗组低于对照组（P<0.05）。治疗后两组患儿BA、HtSDS-BA及BMI比较差异无统计学意义（P>0.05）；治疗组PAH-BA、△GV高于对照组（P<0.05）。两组不良反应总发生率比较差异无统计学意义（P>0.05）。结论：重组人生长激素联合亮丙瑞林可明显改善中枢性性早熟患儿的成年预测身高和体内E2、FSH、LH水平 |
| 关键词: 生长激素 中枢性性早熟 促性腺激素释放激素类似物 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2020.07.006 |
|
| 基金项目: |
|
| Recombinant Human Growth Hormone Combined with Leuprorelin in the Treatment of Girls with idiopathic Central Precocious Puberty |
| Wang Xiping, Xu Xu, Jiang Li, Gu Kefeng, Xu Lulian, Liu Zhenzhen, Lu Yang |
| (Wuxi Children’s Hospital, Jiangsu Wuxi 214000, China) |
| Abstract: |
| Objective: To investigate the therapeutic effects of recombinant human growth hormone combined with leuprorelin in the treatment of girls with idiopathic central precocious puberty and its effects on estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Methods: Fifty-six girls with idiopathic central precocious puberty admitted into our hospital from 2016 to 2018 were extracted to be divided into the treatment group and the control group via the random number table, with 28 cases in each group. The control group was treated with leuprorelin alone, while the treatment group additionally received recombinant human growth hormone on the basis of the control group. The bone age (BA), body mass index (BMI), prediction of adult height (PAH-BA), height standarddeviation score (HtSDS-BA), and annual average growth rate (△GV) of two groups were observed after treatment. Results: There was no statistically significant difference in breast development age, age at treatment, height, BA, PAH-BA, HtSDS-BA, genetic target height, BMI, left ovary volume, right ovary volume, uterine volume and △GV between two groups (P>0.05). After treatment, the sex hormone levels (E2, LH, FSH) of two groups decreased significantly, and the treatment group was lower than the control group (P<0.05). There was no significant difference in BA, HtSDS-BA and BMI between two groups after treatment (P>0.05). PAH-BA and △GV in the treatment group were higher than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse drug reactions between two groups (P>0.05). Conclusion: Recombinant human growth hormone combined with leuprorelin can significantly improve the predicted height and the levels of E2, FSH and LH in vivo in children with idiopathic central precocious puberty |
| Key words: growth hormone central precious puberty gonadotropin releasing hormone analogue |
